Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • Nebraska


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com

Omaha

Lincoln

Bellevue

Grand Island

Kearney

Fremont

Hastings

North Platte

Norfolk

Columbus

Yutan


Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Using VR to Assess the Efficacy of a Motivational Interviewing Intervention to Increase Bystander Behaviors
    NCT04160702
    Condition:   Sexual Assault
    Intervention:   Behavioral: Motivate-The-Bystander (MTB)
    Sponsors:   University of Nebraska Lincoln;   University of Nebraska
    Recruiting
  • Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
    NCT04138836
    Condition:   Healthy Participants
    Interventions:   Drug: BBT-877;   Drug: Midazolam;   Drug: Itraconazole;   Drug: Esomeprazole
    Sponsors:   Bridge Biotherapeutics, Inc.;   KCRN Research, LLC
    Active, not recruiting
  • A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OTAP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
    NCT04121078
    Condition:   Healthy Volunteers
    Interventions:   Drug: TAK-906;   Drug: Rifampin
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Completed
  • Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
    NCT04092712
    Condition:   Healthy Volunteers
    Intervention:   Drug: [14C]-CTP-543
    Sponsors:   Concert Pharmaceuticals;   Celerion
    Completed
  • Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects
    NCT04044339
    Condition:   Healthy
    Interventions:   Drug: TD-5202;   Drug: Placebo
    Sponsor:   Theravance Biopharma
    Recruiting
  • Comparison of a Non-linear Analysis of Balance During the mBESS to the Sway Balance Application
    NCT03994952
    Condition:   Healthy Volunteers
    Interventions:   Device: Sway Balance Application;   Device: Balance Tracking Systems
    Sponsor:   University of Nebraska
    Recruiting
  • Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects
    NCT03830125
    Condition:   Idiopathic Pulmonary Fibrosis
    Interventions:   Drug: BBT-877, Single dose;   Drug: Placebo group;   Drug: BBT-877, Multiple doses
    Sponsors:   Bridge Biotherapeutics, Inc.;   KCRN Research, LLC
    Recruiting
  • Resistance Exercise and Protein During Weight Loss
    NCT03600311
    Conditions:   Weight Loss;   Starvation
    Interventions:   Other: Caloric Restriction;   Dietary Supplement: Post-Exercise Protein;   Other: Energy Balance;   Dietary Supplement: Post-Exercise Carbohydrate;   Dietary Supplement: Calcium and Vitamin D
    Sponsor:   University of Nebraska Lincoln
    Completed
  • To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers
    NCT03543137
    Condition:   Tobacco Use Disorder
    Interventions:   Drug: Nicotine Prototype Mini lozenge;   Drug: Nicorette Mini Lozenge
    Sponsor:   GlaxoSmithKline
    Completed
  • Finances First: A Health Intervention in Low Income Single Mother Households
    NCT03035240
    Condition:   Financial Stress
    Intervention:   Behavioral: Financial Education
    Sponsor:   Creighton University
    Recruiting
  • TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
    NCT02772159
    Condition:   Chronic Obstructive Pulmonary Disease (COPD)
    Intervention:   Drug: TD-4208
    Sponsor:   Theravance Biopharma
    Completed
  • Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center
    NCT02409147
    Condition:   Uterus Transplant
    Intervention:   Procedure: Uterine Transplant
    Sponsor:   University of Nebraska
    Withdrawn
  • A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
    NCT02288481
    Condition:   Tuberculosis
    Interventions:   Drug: TBA-354;   Other: Placebo
    Sponsor:   Global Alliance for TB Drug Development
    Completed
  • PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)
    NCT02216331
    Condition:   Tuberculosis
    Interventions:   Drug: TMC207;   Drug: rifapentine;   Drug: rifampicin
    Sponsor:   Global Alliance for TB Drug Development
    Completed
  • Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)
    NCT01830439
    Condition:   Tuberculosis
    Interventions:   Drug: PA-824 200mg;   Drug: PA-824 50mg
    Sponsor:   Global Alliance for TB Drug Development
    Completed
  • Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam
    NCT01768273
    Condition:   Tuberculosis
    Interventions:   Drug: Midazolam;   Drug: PA-824
    Sponsor:   Global Alliance for TB Drug Development
    Completed
  • Pilot Study- Treat to Target Vitamin D in End Stage Renal Disease
    NCT04167111
    Condition:   Chronic Kidney Diseases
    Intervention:   Dietary Supplement: Cholecalciferol
    Sponsors:   University of Nebraska;   University of Nebraska, Omaha
    Not yet recruiting
  • Uphill Walking as Exercise for COPD Patients
    NCT04026529
    Condition:   Chronic Obstructive Pulmonary Disease
    Intervention:   Other: walking on incline or walking at increasing speed
    Sponsors:   VA Office of Research and Development;   University of Nebraska, Omaha
    Not yet recruiting
  • A Study to Assess Tobacco-related Biomarkers of Exposure in Smokers Using myBlu E-cigarettes
    NCT04019626
    Condition:   Healthy Volunteers
    Interventions:   Other: Continue-smoking;   Other: myblu Tobacco Chill 2.5%;   Other: myblu Tobacco Chill 4.0%;   Other: myblu Honeymoon 2.5%;   Other: myblu Honeymoon 4.0%
    Sponsor:   Fontem Ventures BV
    Recruiting
  • Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE
    NCT03998176
    Condition:   HIV-1-infection
    Intervention:   Drug: Bictegravir/emtricitabine/tenofovir alafenamide
    Sponsors:   University of Nebraska;   Gilead Sciences
    Recruiting
  • Evaluation of the Spry Belt for Improving Bone Quality
    NCT03986203
    Condition:   Osteopenia
    Intervention:   Device: Spry Belt
    Sponsors:   Theranova, L.L.C.;   National Institute on Aging (NIA);   University of Nebraska
    Recruiting
  • A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants
    NCT03961295
    Condition:   Healthy Volunteers
    Intervention:   Drug: Vedolizumab SC
    Sponsor:   Takeda
    Completed
  • Impact of Evolocumab in Cardiac Transplant Patients With CAV
    NCT03944577
    Condition:   Heart Transplant
    Intervention:   Drug: Evolocumab (Repatha)
    Sponsors:   University of Nebraska;   Amgen
    Recruiting
  • ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
    NCT03932643
    Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Intervention:   Drug: ONC201
    Sponsor:   Vijaya Bhatt
    Recruiting
  • Restoring Cognitive Control in Acute Nicotine Withdrawal
    NCT03887429
    Condition:   Impulse Control Disorders
    Interventions:   Drug: SXC-2023;   Drug: Placebos
    Sponsors:   Promentis Pharmaceuticals, Inc.;   Baylor College of Medicine;   Celerion
    Completed
  • Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults
    NCT03858075
    Condition:   Healthy Volunteers
    Interventions:   Drug: BLU-782;   Drug: Placebo;   Drug: BLU-782 taken with food
    Sponsor:   Blueprint Medicines Corporation
    Completed
  • Biomarker Assessments of Leukine During Treatment of Parkinson's Disease
    NCT03790670
    Condition:   Parkinson Disease
    Intervention:   Drug: sargramostim
    Sponsor:   University of Nebraska
    Active, not recruiting
  • Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience
    NCT03724331
    Conditions:   Fatigue;   Self Efficacy;   Quality of Life;   Physical Activity;   Lung Cancer;   Non-Small Cell Lung Cancer
    Interventions:   Behavioral: Light Physical Activity 1;   Behavioral: Light Physical Activity 2;   Behavioral: Support Education Activity
    Sponsors:   University of Nebraska;   Spectrum Health Hospitals;   Ingham Regional Medical Center;   Sparrow Clinical Research Institute;   Munson Medical Center
    Recruiting
  • Effect of Vitamin D Supplementation on Balance in CKD
    NCT03710161
    Conditions:   Renal Insufficiency, Chronic;   Kidney Failure, Chronic
    Intervention:   Drug: Vitamin D
    Sponsor:   University of Nebraska
    Recruiting
  • Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
    NCT03662295
    Conditions:   Migraine Disorders;   Aphasia
    Intervention:   Behavioral: Language treatment
    Sponsor:   Quality Living, Inc.
    Completed
  • Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities
    NCT03574207
    Conditions:   Mild Cognitive Impairment;   Memory Loss
    Intervention:   Device: Transcranial magnetic stimulation
    Sponsors:   University of Nebraska;   National Institute of General Medical Sciences (NIGMS)
    Recruiting
  • Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
    NCT03476174
    Condition:   Melanoma
    Interventions:   Drug: Pembrolizumab;   Drug: Interleukin-2
    Sponsors:   Ralph Hauke;   Nebraska Cancer Specialists; Midwest Cancer Center-Legacy;   Prometheus Laboratories
    Terminated
  • Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
    NCT03386500
    Conditions:   Anal Cancer, Squamous Cell Carcinoma;   Radiation Exposure
    Intervention:   Drug: BMX-001
    Sponsors:   Chi Lin, MD;   BioMimetix JV, LLC;   University of Nebraska
    Recruiting
  • Engaging Rural Men With Mobile Technologies for Weight Loss
    NCT03329079
    Condition:   Weight Loss
    Interventions:   Behavioral: Mobile Technology Plus;   Behavioral: Mobile Technology
    Sponsors:   University of Nebraska;   Northeast Nebraska Public Health Department
    Active, not recruiting
  • Language Assessment and Treatment Following Acquired Brain Injury
    NCT03320954
    Condition:   Brain Injuries
    Intervention:   Behavioral: Anomia treatment
    Sponsor:   University of Nebraska Lincoln
    Completed
  • Preventing Diabetes With Digital Health and Coaching
    NCT03312764
    Condition:   PreDiabetes
    Interventions:   Behavioral: Online diabetes prevention program;   Behavioral: Standard Care
    Sponsors:   Omada Health, Inc.;   University of Nebraska;   Wake Forest University Health Sciences
    Active, not recruiting
  • Impact of Oral Hygiene Gels on Peri-implant Mucositis
    NCT03243591
    Condition:   Mucositis
    Interventions:   Other: Livionex gel;   Other: Aquafresh gel
    Sponsor:   University of Nebraska
    Completed
  • Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults With Acute Myeloid Leukemia
    NCT03226418
    Conditions:   Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Decitabine;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Azacitidine;   Drug: Venetoclax;   Drug: glasdegib
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting
  • Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066
    NCT03198767
    Condition:   Obesity
    Interventions:   Drug: LIK066;   Dietary Supplement: Carbohydrate 50%;   Dietary Supplement: Carbohydrate 25%;   Dietary Supplement: Carbohydrate 8%;   Dietary Supplement: Carbohydrate 0%;   Dietary Supplement: Psyllium;   Dietary Supplement: Calcium carbonate
    Sponsor:   Novartis Pharmaceuticals
    Completed
  • Early Rheumatoid Arthritis Lung Disease Study
    NCT03192267
    Condition:   Rheumatoid Arthritis
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting
  • Intensive Referral to Reduce Smoking in Probationers
    NCT03042650
    Conditions:   Smoking Cessation;   Substance Use Disorder
    Interventions:   Behavioral: Intensive Referral Intervention Group;   Behavioral: Standard Practice Facilitated Group
    Sponsor:   University of Nebraska
    Active, not recruiting
  • Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients
    NCT03039569
    Condition:   Diabetes Mellitus, Type 2
    Intervention:   Behavioral: Text messaging
    Sponsors:   University of Nebraska Lincoln;   The Methodist Hospital System
    Completed
  • TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    NCT02874404
    Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: PI3K-delta Inhibitor TGR-1202
    Sponsors:   Matthew Lunning, DO;   National Cancer Institute (NCI)
    Completed
  • Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
    NCT02833701
    Conditions:   Glioblastoma;   Glioma
    Interventions:   Dietary Supplement: Ascorbic Acid;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Terminated
  • Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
    NCT02767388
    Conditions:   Myelodysplastic Syndrome;   Effects of Chemotherapy;   Mild Cognitive Impairment;   Multiple Myeloma;   Non-hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphoid Leukemia;   Chronic Myeloid Leukemia;   Acute Myeloid Leukemia
    Intervention:  
    Sponsor:   University of Nebraska
    Completed
  • Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia
    NCT02647892
    Condition:   Local Anesthesia
    Interventions:   Drug: lidocaine;   Drug: sodium bicarbonate
    Sponsor:   University of Nebraska
    Enrolling by invitation
  • Cholecalciferol in Treating Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency
    NCT02553447
    Conditions:   Chronic Lymphocytic Leukemia;   Non-Hodgkin Lymphoma;   Untreated Chronic Lymphocytic Leukemia;   Vitamin D Deficiency
    Interventions:   Dietary Supplement: Cholecalciferol;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting
  • Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12-36 Months of Age With Serologic Evidence of Prior Exposure
    NCT04144348
    Condition:   Human Metapneumovirus and Human Parainfluenza Infection
    Interventions:   Biological: mRNA-1653;   Biological: Placebo
    Sponsor:   ModernaTX, Inc.
    Recruiting
  • Phase 1 Study of ACE-083 in Healthy Subjects
    NCT02257489
    Condition:   Musculoskeletal Diseases
    Intervention:   Drug: ACE-083
    Sponsor:   Acceleron Pharma, Inc.
    Completed
  • Measurement of Beta Cell Death in Individuals With Cystic Fibrosis
    NCT03713437
    Condition:   Cystic Fibrosis-related Diabetes
    Intervention:   Diagnostic Test: Measurement of differentially methylated insulin DNA
    Sponsors:   University of Nebraska;   Cystic Fibrosis Foundation
    Recruiting
  • Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer
    NCT01959672
    Conditions:   Pancreatic Adenocarcinoma;   Resectable Pancreatic Carcinoma;   Stage I Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
    Interventions:   Procedure: 4-Dimensional Computed Tomography;   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Nelfinavir Mesylate;   Biological: Oregovomab;   Radiation: Stereotactic Body Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Completed
  • A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
    NCT03574584
    Conditions:   Metabolism and Nutrition Disorders;   Overweight or Obesity
    Interventions:   Drug: NNC0165-1562;   Drug: Semaglutide;   Drug: Placebo (NNC0165-1562)
    Sponsor:   Novo Nordisk A/S
    Completed
  • Effects of Octacosanol During Taekwondo Training
    NCT03557476
    Conditions:   Oxidative Stress;   Dyslipidemias
    Interventions:   Dietary Supplement: Octacosanol;   Dietary Supplement: Placebo
    Sponsor:   University of Nebraska, Omaha
    Completed
  • Mobility Exercises for Gait (MEG Neuroplasticity Project)
    NCT03555708
    Condition:   Cerebral Palsy
    Intervention:   Other: Physical Therapy
    Sponsor:   University of Nebraska
    Recruiting
  • Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp
    NCT01930539
    Conditions:   Vitamin D Deficiency;   Short Bowel Syndrome
    Intervention:   Device: Ultraviolet B lamp
    Sponsor:   University of Nebraska
    Completed
  • Resurgence as Choice: Basic and Clinical Studies
    NCT03423940
    Conditions:   Increasing Functional Communicative Behavior;   Decreasing Destructive Behavior;   Analysis of Treatment Dosage;   Empirically Determined Reinforcement Schedule Thinning
    Interventions:   Behavioral: Functional communication training;   Behavioral: RaC-enhanced functional communication training
    Sponsors:   University of Nebraska;   Utah State University
    Recruiting
  • Feasibility of a Touch Screen Computer Based Breast-feeding Educational Support Program
    NCT03308058
    Condition:   Pregnancy Related
    Intervention:   Behavioral: Breastfeeding computer education
    Sponsor:   University of Nebraska
    Completed
  • Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer
    NCT01307956
    Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Adenocarcinoma;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer
    Interventions:   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Panitumumab;   Other: Pharmacological Study;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Terminated
  • Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control
    NCT02483572
    Conditions:   Aggression;   Self-Injurious Behavior
    Intervention:   Behavioral: Functional Communication Training
    Sponsor:   University of Nebraska
    Terminated
  • Stereotactic Radiation Therapy, Nelfinavir Mesylate, Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Locally Advanced Pancreatic Cancer
    NCT01068327
    Conditions:   Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Drug: nelfinavir mesylate;   Radiation: stereotactic body radiation therapy;   Radiation: hypofractionated radiation therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Completed
  • Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
    NCT01052051
    Condition:   Cancer
    Interventions:   Dietary Supplement: Vitamin D3;   Dietary Supplement: Calcium carbonate
    Sponsors:   Creighton University;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Completed
  • Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
    NCT00856037
    Condition:   Recurrent Small Cell Lung Carcinoma
    Interventions:   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: Topotecan Hydrochloride
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Completed
  • Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders
    NCT01867398
    Conditions:   Conduct Disorder;   fMRI
    Intervention:  
    Sponsors:   National Institute of Mental Health (NIMH);   Boys Town Research Hospital
    Terminated
  • Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison
    NCT00626366
    Condition:   Chronic Sinusitis
    Interventions:   Radiation: Sinus CT Scan;   Drug: Omnipaque 240 Contrast Solution;   Drug: Omnipaque 240 mg I/mL
    Sponsor:   University of Nebraska
    Completed
  • CT Scans in Screening for Lung Cancer in Current and Former Smokers
    NCT00625690
    Condition:   Lung Cancer
    Interventions:   Other: questionnaire administration;   Procedure: computed tomography;   Procedure: evaluation of cancer risk factors;   Procedure: study of high risk factors
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Completed
  • Role of Apathy in the Effectiveness of Weight Loss Interventions
    NCT00548652
    Conditions:   Obesity;   Apathy
    Interventions:   Behavioral: MOVE;   Behavioral: medical crisis councelling;   Drug: methyphenidate
    Sponsor:   VA Nebraska Western Iowa Health Care System
    Completed
  • Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
    NCT00089024
    Condition:   Pancreatic Cancer
    Interventions:   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Completed
  • Validity of Physical Activity Questionnaires in Persons Pursuing Bariatric Surgery
    NCT03981978
    Conditions:   Bariatric Surgery Candidate;   Obesity
    Intervention:   Behavioral: Physical Activity
    Sponsor:   University of Nebraska
    Not yet recruiting
  • Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic
    NCT03431831
    Condition:   Obesity
    Interventions:   Behavioral: Intervention Control;   Behavioral: Counselling;   Drug: Contrave;   Drug: Contrave and Counseling
    Sponsor:   University of Nebraska
    Active, not recruiting
  • CALLiNGS Protocol: Care Across Locations Longitudinally in Navigation of Goals and Symptoms
    NCT03999957
    Condition:   Palliative Care
    Intervention:   Other: Telehealth web conferencing
    Sponsor:   University of Nebraska
    Recruiting
  • Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
    NCT01994174
    Condition:   Macular Disease
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting
  • Bupropion in the Treatment of Methamphetamine Dependence
    NCT00572234
    Condition:   Methamphetamine Use Disorder
    Intervention:   Drug: bupropion SR
    Sponsor:   University of Nebraska
    Completed
  • First-Sight Refractive Error Correction: Direct Comparison to Autorefraction Results in Children 7 to 18 Years of Age
    NCT01365884
    Condition:   Refractive Error
    Intervention:  
    Sponsor:   University of Nebraska
    Terminated
  • Pain Management Following Sinus Surgery
    NCT03822962
    Conditions:   Nasal Sinus; Inflammation;   Opioid Abuse;   Pain, Postoperative
    Interventions:   Drug: Ibuprofen 600Mg Tablet;   Other: Standard Regimen | Tylenol
    Sponsor:   University of Nebraska
    Recruiting
  • A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants
    NCT03961308
    Condition:   Healthy Volunteers
    Intervention:   Drug: Vedolizumab SC
    Sponsor:   Takeda
    Completed
  • Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery
    NCT02654119
    Conditions:   HER2 Positive Breast Carcinoma;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Trastuzumab
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Active, not recruiting
  • An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers
    NCT03882359
    Condition:   Heart Diseases
    Interventions:   Diagnostic Test: Echocardiogram;   Drug: MVT-100;   Drug: Definity
    Sponsors:   Microvascular Therapeutics, LLC;   National Heart, Lung, and Blood Institute (NHLBI);   University of Nebraska
    Recruiting
  • Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
    NCT03737123
    Condition:   Urothelial Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Gemcitabine;   Drug: Atezolizumab;   Drug: Docetaxel
    Sponsors:   Nabil Adra;   Genentech, Inc.;   Indiana University School of Medicine
    Recruiting
  • Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
    NCT02524275
    Condition:   Head and Neck Squamous Cell Carcinoma
    Interventions:   Drug: Capecitabine;   Drug: Docetaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   University of Nebraska
    Recruiting
  • Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
    NCT03007979
    Conditions:   Breast Cancer;   Breast Carcinoma;   Cancer of Breast;   Malignant Tumor of Breast
    Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Procedure: Optional research biopsy;   Drug: Goserelin;   Procedure: Research blood draw;   Procedure: Circulating tumor cell blood draw;   Procedure: Tumor biopsy (optional)
    Sponsors:   Washington University School of Medicine;   Pfizer
    Recruiting
  • 12 Weeks of Resistance Band Exercise Impacts on Metabolic Syndrome Progression in Postmenopausal Women
    NCT04014686
    Conditions:   Metabolic Syndrome;   Dyslipidemias;   Insulin Resistance;   Hypertension
    Interventions:   Other: No exercise intervention group;   Behavioral: Resistance band exercise intervention group
    Sponsor:   Pusan National University
    Completed
  • Study on Physical Activity's Relationship With Cancer and Cognition
    NCT03980626
    Conditions:   Breast Cancer;   Breast Neoplasm Female
    Intervention:   Behavioral: Walking
    Sponsor:   University of Nebraska
    Recruiting
  • Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO
    NCT03673566
    Conditions:   Preterm Birth;   Low; Birthweight, Extremely (999 Grams or Less);   Neonatal Infection;   Satisfaction;   Stress;   Chronic Lung Disease;   Growth Acceleration;   Adverse Event
    Intervention:   Device: NICU Dashboard
    Sponsors:   Philips Healthcare;   Children's Hospital and Medical Center, Omaha, Nebraska
    Recruiting
  • Treatment for Reading and Writing Deficits Following Acquired Brain Injury
    NCT03662243
    Conditions:   Acquired Brain Injury;   Alexia;   Agraphia
    Intervention:   Behavioral: Multicomponent reading and writing treatment
    Sponsor:   Quality Living, Inc.
    Enrolling by invitation
  • Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
    NCT03186378
    Condition:   Molluscum Contagiosum
    Intervention:   Combination Product: VP-102 with applicator
    Sponsors:   Verrica Pharmaceuticals Inc.;   Paidion Research, Inc.;   Database Integrations, Inc.;   Cato Research;   Instat services
    Completed
  • Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis
    NCT03010228
    Condition:   Lyme Borreliosis, Nervous System
    Interventions:   Biological: VLA15 with Alum;   Biological: VLA15 without Alum
    Sponsor:   Valneva Austria GmbH
    Completed
  • Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis
    NCT00826020
    Conditions:   Parenteral Nutrition Associated Liver Disease PNALD;   Cholestasis
    Intervention:   Drug: Omegaven™
    Sponsor:   University of Nebraska
    Completed
  • Specialized Substance Abuse Supervision (SSAS) Versus Non-SSAS Recidivism Rates Among Nebraska Felony Drug Offenders
    NCT00690352
    Conditions:   Substance-related Disorders;   Alcohol-related Disorders
    Intervention:   Behavioral: Specialized Substance Abuse Supervision (SSAS)
    Sponsor:   University of Nebraska
    Completed
  • Self-Management App for Patients With Left-Ventricular Assist Devices
    NCT03049748
    Condition:   Heart Failure
    Interventions:   Device: Mobile phone app (VAD Care App);   Other: Usual LVAD Care
    Sponsors:   University of Michigan;   Washington University School of Medicine;   National Institute of Nursing Research (NINR)
    Completed
  • Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
    NCT02062632
    Conditions:   Esophageal Carcinoma;   Hypopharyngeal Carcinoma;   Laryngeal Carcinoma;   Lymphoma;   Mesothelioma;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pleura;   Metastatic Malignant Neoplasm in the Spinal Cord;   Non-Small Cell Lung Carcinoma;   Sarcoma;   Small Cell Lung Carcinoma;   Thymic Carcinoma;   Thymoma;   Thyroid Gland Carcinoma
    Interventions:   Drug: Doxepin Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Terminated
  • Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
    NCT03598998
    Conditions:   Anaplastic Large Cell Lymphoma;   Nodal Peripheral T-Cell Lymphoma With TFH Phenotype;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Angioimmunoblastic T-Cell Lymphoma;   Recurrent Enteropathy-Associated T-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hepatosplenic T-Cell Lymphoma;   Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Angioimmunoblastic T-Cell Lymphoma;   Refractory Enteropathy-Associated T-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Hepatosplenic T-Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Subcutaneous Panniculitis-Like T-Cell Lymphoma
    Interventions:   Biological: Pembrolizumab;   Drug: Pralatrexate
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • Venetoclax in Treating Participants With Recurrent or Refractory Mature T-Cell Lymphoma
    NCT03534180
    Conditions:   Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Venetoclax
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy
    NCT01035463
    Conditions:   Anaplastic Large Cell Lymphoma, ALK-Negative;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Lenalidomide;   Drug: Melphalan;   Biological: Rituximab
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Completed
  • Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer
    NCT01880528
    Conditions:   Dyspnea;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer
    Interventions:   Drug: lisinopril;   Drug: placebo
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Active, not recruiting
  • Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
    NCT01431209
    Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Ruxolitinib Phosphate
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Active, not recruiting
  • Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
    NCT00717522
    Condition:   Soft Tissue Sarcoma
    Intervention:   Drug: Pomalidomide
    Sponsor:   Celgene
    Terminated
  • Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
    NCT04064905
    Condition:   Zika Virus
    Interventions:   Biological: mRNA-1893;   Other: Placebo
    Sponsors:   ModernaTX, Inc.;   Biomedical Advanced Research and Development Authority
    Recruiting
  • Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
    NCT04067011
    Condition:   Anthrax
    Interventions:   Drug: Ciprofloxacin 500Mg Tablet;   Drug: Doxycycline 100Mg Tablet;   Biological: AV7909
    Sponsors:   Emergent Product Development Gaithersburg, Inc.;   Biomedical Advanced Research and Development Authority
    Recruiting
  • Validation of Patient Reported Outcome Measures for Use in Vulvodynia
    NCT03770169
    Condition:   Vulvodynia
    Intervention:  
    Sponsor:   Ipsen
    Completed
  • Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
    NCT03616184
    Condition:   Graft-versus-host-disease (GVHD)
    Intervention:   Drug: Ruxolitinib
    Sponsor:   University of Nebraska
    Recruiting
  • HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
    NCT03575910
    Conditions:   Heart Transplant Failure and Rejection;   Heart Failure;   Heart Diseases;   Heart Failure,Congestive;   Transplant; Failure, Heart;   Transplant Failure
    Intervention:  
    Sponsors:   University of British Columbia;   Canadian Institutes of Health Research (CIHR);   PROOF Centre of Excellence;   Duke University;   University of Nebraska;   Toronto General Hospital;   St. Paul's Hospital, Canada
    Recruiting
  • Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
    NCT02673255
    Condition:   Healthy
    Intervention:   Biological: Tetanus and Diphtheria (Td) Vaccine
    Sponsors:   Biomat USA, Inc.;   Hammond Clinical Trial Consulting, LLC;   Axio Research. LLC
    Active, not recruiting
  • Smith-Lemli-Opitz Syndrome and Cholic Acid
    NCT03720990
    Condition:   Smith-Lemli-Opitz Syndrome
    Intervention:   Drug: Cholic Acid
    Sponsors:   University of Nebraska;   University of Colorado, Denver;   Children's Hospital Medical Center, Cincinnati;   University of Pittsburgh
    Not yet recruiting
  • A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
    NCT02990468
    Condition:   Head and Neck Cancer
    Interventions:   Drug: BMX-001;   Radiation: Radiation Therapy;   Drug: Cisplatin
    Sponsors:   BioMimetix JV, LLC;   Duke University
    Recruiting
  • A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas
    NCT03316573
    Conditions:   Lymphoma;   Histiocytic Sarcoma;   Follicular Dendritic Cell Sarcoma;   Interdigitating Dendritic Cell Sarcoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
    Recruiting
  • A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
    NCT02967133
    Conditions:   Non-Small-Cell Lung Cancer Metastatic;   Non-Small Cell Carcinoma of Lung, TNM Stage 4;   Nonsmall Cell Lung Cancer;   Non Small Cell Lung Cancer Recurrent
    Interventions:   Drug: Nivolumab;   Drug: nab-paclitaxel
    Sponsors:   Alliance Foundation Trials, LLC.;   Celgene Corporation;   Bristol-Myers Squibb
    Active, not recruiting
  • Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus
    NCT02445911
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: KQ-791;   Drug: Placebo
    Sponsor:   Kaneq Bioscience Limited
    Completed
  • ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
    NCT00477529
    Condition:   Hormone Refractory Prostate Cancer
    Intervention:   Drug: ABI-008
    Sponsor:   Celgene
    Completed
  • A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
    NCT04032093
    Condition:   Respiratory Tract Infection
    Interventions:   Biological: RSV vaccine;   Biological: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
    NCT03828617
    Condition:   Pneumococcal Disease
    Interventions:   Biological: 20vPnC;   Biological: 13vPnC
    Sponsor:   Pfizer
    Completed
  • LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
    NCT03412890
    Conditions:   Heavy Menstrual Bleeding;   Uterine Fibroid
    Interventions:   Drug: Relugolix;   Drug: Estradiol/norethindrone acetate
    Sponsor:   Myovant Sciences GmbH
    Active, not recruiting
  • Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults
    NCT03301051
    Conditions:   Virus Diseases;   RNA Virus Infections;   Respiratory Tract Diseases;   Respiratory Tract Infections
    Interventions:   Biological: Quadrivalent VLP Vaccine;   Biological: Placebo
    Sponsor:   Medicago
    Completed
  • Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
    NCT03150693
    Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Drug: Allopurinol;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Pegylated L-Asparaginase;   Drug: Methotrexate;   Procedure: Bone Marrow Aspiration and Biopsy;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Rituximab;   Drug: Doxorubicin;   Drug: Thioguanine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
    NCT03049735
    Conditions:   Heavy Menstrual Bleeding;   Uterine Fibroid
    Interventions:   Drug: Relugolix;   Drug: Estradiol/norethindrone acetate;   Drug: Placebo for E2/NETA;   Drug: Placebo for relugolix
    Sponsor:   Myovant Sciences GmbH
    Active, not recruiting
  • A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
    NCT03311555
    Condition:   Prostate Cancer
    Interventions:   Drug: Apalutamide;   Drug: Androgen deprivation;   Radiation: Salvage radiation therapy;   Drug: Docetaxel
    Sponsor:   Tian Zhang, MD
    Recruiting
  • A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
    NCT02624947
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Biological: RSV F vaccine with adjuvant;   Biological: Formulation buffer
    Sponsors:   Novavax;   Bill and Melinda Gates Foundation
    Completed
  • Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
    NCT04003103
    Condition:   HIV-1 Infection
    Interventions:   Drug: Islatravir;   Drug: Placebo
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
    NCT03520517
    Conditions:   Amyotrophic Lateral Sclerosis;   ALS;   Lou Gehrig Disease;   Lou Gehrig's Disease;   Lou-Gehrigs Disease;   Motor Neuron Disease, Amyotrophic Lateral Sclerosis
    Intervention:   Drug: BHV-0223
    Sponsors:   Biohaven Pharmaceuticals, Inc.;   Cognitive Research Corporation
    Completed
  • Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology
    NCT03699514
    Conditions:   Healthy;   Cognitive Impairment;   Neurological Disorder
    Intervention:   Device: Brain Network Activation (BNA™) technology
    Sponsor:   ElMindA Ltd
    Recruiting
  • PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
    NCT04142658
    Conditions:   Aortic Valve Disease;   Aortic Valve Stenosis;   Aortic Valve Failure
    Interventions:   Drug: Apixaban 5 MG;   Drug: Apixaban 2.5 MG;   Drug: Warfarin;   Device: On-X Aortic Mechanical Valve
    Sponsors:   CryoLife, Inc.;   Duke Clinical Research Institute
    Not yet recruiting
  • A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation
    NCT04029545
    Condition:   Lip Augmentation
    Intervention:   Device: PN40082
    Sponsors:   Prollenium Medical Technologies Inc.;   Symbio, LLC
    Active, not recruiting
  • High Dose IL 2 and Entinostat in RCC
    NCT03501381
    Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Entinostat;   Drug: Interleukin-2
    Sponsors:   Roberto Pili;   Indiana University Melvin and Bren Simon Cancer Center;   Prometheus Laboratories;   Syndax Pharmaceuticals
    Recruiting
  • Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer
    NCT04095364
    Conditions:   Low Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal Low Grade Serous Adenocarcinoma;   Stage II Ovarian Cancer AJCC v8;   Stage IIA Ovarian Cancer AJCC v8;   Stage IIB Ovarian Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Drug: Letrozole;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
    NCT03971474
    Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Guiding Treatment for Patients With Brain Metastases
    NCT03994796
    Conditions:   CDK Gene Mutation;   Metastatic Malignant Neoplasm in the Brain;   Metastatic Malignant Solid Neoplasm;   NTRK Family Gene Mutation;   PI3K Gene Mutation;   ROS1 Gene Mutation
    Interventions:   Drug: Abemaciclib;   Drug: PI3K Inhibitor GDC-0084;   Drug: Entrectinib
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Genentech, Inc.
    Recruiting
  • Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
    NCT03937635
    Condition:   Smoldering Plasma Cell Myeloma
    Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
    NCT03851445
    Condition:   Previously Treated Non-Small Cell Lung Cancer
    Intervention:   Drug: Screening Platform
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
    NCT03866382
    Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
    NCT03793179
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
    NCT03793166
    Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
    NCT03768414
    Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)
    NCT03737994
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer
    NCT03811015
    Conditions:   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
    NCT03723928
    Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
    Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
    NCT03698019
    Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
    NCT03701282
    Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
    NCT03694002
    Conditions:   Locally Advanced Thymic Carcinoma;   Metastatic Thymic Carcinoma;   Recurrent Thymic Carcinoma;   Unresectable Thymic Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ramucirumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer
    NCT03660826
    Conditions:   Endometrial Undifferentiated Carcinoma;   Endometrioid Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
    Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
    NCT03654768
    Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
    NCT03839940
    Condition:   Malignant Neoplasm
    Interventions:   Drug: Dexamethasone;   Other: Placebo;   Other: Questionnaire;   Other: Quality-of-Life Assessment;   Drug: Everolimus
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab and Epacadostat in Treating Patients With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma
    NCT03602586
    Conditions:   Malignant Ovarian Clear Cell Tumor;   Recurrent Ovarian Carcinoma
    Interventions:   Drug: Epacadostat;   Biological: Pembrolizumab
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Suspended
  • Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
    NCT03609216
    Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma
    Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Biological: Pegfilgrastim;   Procedure: Conventional Surgery;   Procedure: Radical Cystectomy;   Other: Chemoradiotherapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
    NCT03499808
    Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
    Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
    NCT03468985
    Conditions:   Metastatic Lung Non-Squamous Non-Small Cell Carcinoma;   Recurrent Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
    NCT03414970
    Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
    Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
    NCT03418961
    Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
    NCT03382561
    Conditions:   Extensive Stage Lung Small Cell Carcinoma;   Recurrent Lung Small Cell Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
    NCT03578081
    Condition:   Malignant Neoplasm
    Interventions:   Drug: Palonosetron Hydrochloride;   Drug: Ondansetron Hydrochloride;   Drug: Dexamethasone;   Drug: Fosaprepitant Dimeglumine;   Drug: Olanzapine;   Other: Placebo
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
    NCT03365882
    Conditions:   Colon Adenocarcinoma;   ERBB2 Gene Amplification;   Rectal Adenocarcinoma;   Recurrent Colon Carcinoma;   Recurrent Rectal Carcinoma;   Stage III Colon Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIA Rectal Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIB Rectal Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7;   Stage IIIC Rectal Cancer AJCC v7;   Stage IV Colon Cancer AJCC v7;   Stage IV Rectal Cancer AJCC v7;   Stage IVA Colon Cancer AJCC v7;   Stage IVA Rectal Cancer AJCC v7;   Stage IVB Colon Cancer AJCC v7;   Stage IVB Rectal Cancer AJCC v7
    Interventions:   Biological: Cetuximab;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Biological: Trastuzumab;   Device: HER-2 testing
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
    NCT03233711
    Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Other: Patient Observation
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
    NCT03228537
    Conditions:   Biphasic Mesothelioma;   Epithelioid Mesothelioma;   Stage I Pleural Malignant Mesothelioma AJCC v7;   Stage IA Pleural Malignant Mesothelioma AJCC v7;   Stage IB Pleural Malignant Mesothelioma AJCC v7;   Stage II Pleural Malignant Mesothelioma AJCC v7;   Stage III Pleural Malignant Mesothelioma AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Cisplatin;   Procedure: Extrapleural Pneumonectomy;   Drug: Pemetrexed Disodium;   Procedure: Pleurectomy;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
    NCT03087708
    Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    NCT03092674
    Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Suspended
  • Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
    NCT03033576
    Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
    NCT03018249
    Conditions:   FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma;   Uterine Corpus Adenosarcoma
    Interventions:   Drug: Entinostat;   Procedure: Hysterectomy;   Other: Laboratory Biomarker Analysis;   Drug: Medroxyprogesterone Acetate
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
    NCT03518034
    Conditions:   Hypogonadism;   Cardiovascular Diseases
    Interventions:   Drug: Testosterone;   Drug: Placebo
    Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
    NCT02921256
    Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7
    Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Veliparib
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Suspended
  • Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
    NCT02912559
    Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
    NCT02890355
    Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer AJCC v6 and v7
    Interventions:   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
    NCT02893930
    Conditions:   Pancreatic Neuroendocrine Tumor G1;   Pancreatic Neuroendocrine Tumor G2;   Refractory Pancreatic Neuroendocrine Carcinoma
    Intervention:   Drug: Sapanisertib
    Sponsor:   National Cancer Institute (NCI)
    Suspended
  • Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    NCT02839707
    Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Undifferentiated Carcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Undifferentiated Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Suspended
  • Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
    NCT02834013
    Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Suspended
  • Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer
    NCT03304639
    Conditions:   Stage III Merkel Cell Carcinoma AJCC v7;   Stage IIIA Merkel Cell Carcinoma AJCC v7;   Stage IIIB Merkel Cell Carcinoma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7
    Interventions:   Biological: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
    NCT02785952
    Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
    NCT02734537
    Conditions:   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant;   Lip and Oral Cavity Squamous Cell Carcinoma;   p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
    NCT02761057
    Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
    NCT02601209
    Conditions:   High Grade Sarcoma;   Metastatic Leiomyosarcoma;   Metastatic Malignant Peripheral Nerve Sheath Tumor;   Metastatic Synovial Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Metastatic Unresectable Sarcoma;   Myxofibrosarcoma;   Recurrent Leiomyosarcoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Synovial Sarcoma;   Recurrent Undifferentiated Pleomorphic Sarcoma;   Stage III Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IV Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8;   Unresectable Leiomyosarcoma
    Interventions:   Drug: Pazopanib;   Drug: Pazopanib Hydrochloride;   Drug: Sapanisertib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
    NCT02595905
    Conditions:   Breast Carcinoma Metastatic in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
    NCT02523014
    Conditions:   Intracranial Meningioma;   Recurrent Meningioma;   NF2 Gene Mutation
    Interventions:   Drug: vismodegib;   Drug: GSK2256098
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   GlaxoSmithKline;   Genentech, Inc.;   Brain Science Foundation
    Suspended
  • High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
    NCT02506153
    Conditions:   Metastatic Cutaneous Melanoma;   Metastatic Non-Cutaneous Melanoma;   Non-Cutaneous Melanoma;   Recurrent Cutaneous Melanoma;   Recurrent Non-Cutaneous Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage III Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7
    Interventions:   Biological: Ipilimumab;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
    NCT02500797
    Conditions:   Dedifferentiated Liposarcoma;   Gastrointestinal Stromal Tumor;   Locally Advanced Bone Sarcoma;   Locally Advanced Soft Tissue Sarcoma;   Metastatic Bone Sarcoma;   Metastatic Liposarcoma;   Metastatic Soft Tissue Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Metastatic Unresectable Sarcoma;   Pleomorphic Liposarcoma;   Stage III Bone Sarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Bone Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Bone Sarcoma AJCC v7;   Stage IVB Bone Sarcoma AJCC v7;   Unresectable Bone Sarcoma;   Unresectable Liposarcoma;   Unresectable Soft Tissue Sarcoma
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    NCT02498600
    Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
    NCT02595944
    Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Intervention:   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
    NCT02466971
    Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer AJCC v6 and v7;   Stage II Cervical Cancer AJCC v7;   Stage II Vaginal Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7;   Stage IIB Cervical Cancer AJCC v6 and v7;   Stage III Vaginal Cancer AJCC v6 and v7;   Stage IIIB Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVA Vaginal Cancer AJCC v6 and v7;   Vaginal Adenocarcinoma;   Vaginal Adenosquamous Carcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
    Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    NCT02311933
    Conditions:   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
    NCT02257528
    Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Recurrent Cervical Carcinoma;   Stage IV Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVB Cervical Cancer AJCC v6 and v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
    NCT02224781
    Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
    NCT02196181
    Conditions:   BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
    NCT02164916
    Condition:   Colorectal Cancer
    Interventions:   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Drug: vemurafenib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Roche-Genentech
    Active, not recruiting
  • Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
    NCT02154490
    Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Other: Pharmacological Study;   Biological: Rilotumumab;   Drug: Talazoparib;   Drug: Taselisib;   Biological: Tremelimumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
    NCT02134912
    Conditions:   Adenocarcinoma of the Lung;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Drug: crizotinib;   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Terminated
  • Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
    NCT02152982
    Conditions:   Glioblastoma;   Gliosarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Temozolomide;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
    NCT02101788
    Conditions:   Micropapillary Serous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Low Grade Ovarian Serous Adenocarcinoma;   Recurrent Primary Peritoneal Serous Adenocarcinoma
    Interventions:   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment;   Drug: Tamoxifen;   Drug: Tamoxifen Citrate;   Drug: Topotecan;   Drug: Topotecan Hydrochloride;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
    NCT02066181
    Condition:   Desmoid-Type Fibromatosis
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Sorafenib Tosylate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    NCT02048813
    Conditions:   Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
    NCT02003209
    Conditions:   HER2/Neu Positive;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
    Interventions:   Drug: Aromatase Inhibition Therapy;   Drug: Carboplatin;   Other: Cytology Specimen Collection Procedure;   Drug: Docetaxel;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
    NCT01953588
    Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: fulvestrant;   Drug: anastrozole
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Active, not recruiting
  • Integrated Cancer Repository for Cancer Research
    NCT02012699
    Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breast Cancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer;   Neuroendocrine Tumors;   Plasma Cell Dyscrasia;   Healthy Control
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting
  • Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
    NCT01950390
    Conditions:   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
    Interventions:   Biological: Bevacizumab;   Biological: Ipilimumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
    NCT02032823
    Condition:   Breast Cancer
    Interventions:   Drug: Olaparib;   Drug: Placebo
    Sponsors:   AstraZeneca;   Breast International Group;   Frontier Science & Technology Research Foundation, Inc.;   NRG Oncology;   Myriad Genetic Laboratories, Inc.;   Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet;   Merck Sharp & Dohme Corp.
    Active, not recruiting
  • Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
    NCT01896999
    Conditions:   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
    NCT02924727
    Condition:   Acute Myocardial Infarction
    Interventions:   Drug: LCZ696 (sacubitril/valsartan);   Drug: Ramipril;   Drug: Placebo of LCZ696;   Drug: Placebo of ramipril;   Drug: Valsartan;   Drug: Placebo of valsartan
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
    NCT01863550
    Condition:   Plasma Cell Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Active, not recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC